8.2.3 Anti-lymphocyte monoclonal antibodies

Homepage

Search the NeLM

Medicines A-Z

Find key information about medicines by name (prototype)

Browse by Categories:

Browse by NeLM area:

BNF Category

162 library items in 8.2.3 Anti-lymphocyte monoclonal antibodies

Filter results by:

Date Published

NeLM Area

News
Other Library Updates
Health In Focus
Evidence
Medicines A-Z
Communities
Formularies

Results filtered by:

Category

8: Malignant disease and immunosuppression (remove) , 8.2 Drugs affecting the immune response (remove) , 8.2.3 Anti-lymphocyte monoclonal antibodies (remove)

Sort by: Display summary:

Results 1 - 10 of 162

Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next

1.

Outcome at 5 years following response to rituximab therapy in children and adults with ITP

Source: Blood,
Date published: 15/05/2012

Category:

8.2.3 Anti-lymphocyte monoclonal antibodies | Haematology

NeLM Area:

News

Link (abstract)
2.

New national IV monograph on Ofatumumab

Source: Medusa,
Date published: 15/05/2012

Category:

8.2.3 Anti-lymphocyte monoclonal antibodies | Drug Administration

NeLM Area:

News

Link- registration required
3.

Updated national IV monograph on Rituximab

Source: Medusa,
Date published: 04/04/2012

Category:

8.2.3 Anti-lymphocyte monoclonal antibodies | 10.1.3 Drugs that suppress the rheumatic disease process | Drug Administration

NeLM Area:

News

Link- registration required
4.

RCT: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: LUNAR study

Source: Arthritis and Rheumatism,
Date published: 12/01/2012

Category:

8.2.3 Anti-lymphocyte monoclonal antibodies | Renal medicine | Systemic Lupus Erythematosus

NeLM Area:

News

Abstract
5.

Rituximab for relapsing-remitting multiple sclerosis

Source: Cochrane Library,
Date published: 05/01/2012

Category:

8.2.3 Anti-lymphocyte monoclonal antibodies | Drug reviews | Multiple sclerosis

NeLM Area:

Evidence > Drug Specific Reviews

Link to Abstract
6.

Phase II study supports the use of sequential treatment with rituximab and CHOP in PTLD.

Source: Lancet Oncology,
Date published: 14/12/2011

Category:

8.1.1 Alkylating drugs | 8.1.2 Anthracyclines and other cytotoxic antibiotics | 8.2.3 Anti-lymphocyte monoclonal antibodies | Transplantation

NeLM Area:

News

Abstract
7.

NICE issues preliminary guidance (final appraisal determination) on rituximab for follicular lymphoma (review)

Source: NICE,
Date published: 01/12/2011

Category:

8.2.3 Anti-lymphocyte monoclonal antibodies | Clinical guidelines | Lymphoma | National Institute of Clinical Excellence (NICE)

NeLM Area:

News

Link
8.

Intensified ACVBP plus rituximab vs. standard CHOP plus rituximab for diffuse large B-cell lymphoma (LNH03-2B): RCT

Source: Lancet,
Date published: 25/11/2011

Category:

8.1 Cytotoxic drugs | 8.2.3 Anti-lymphocyte monoclonal antibodies | Lymphoma

NeLM Area:

News

Abstract

Comment- full text access limited to subscribers
9.

Review: Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system

Source: Arthritis and Rheumatism,
Date published: 31/10/2011

Category:

8.2.3 Anti-lymphocyte monoclonal antibodies | Rheumatoid Arthritis

NeLM Area:

News

Link (abstract)
10.

Fludarabine plus alemtuzumab vs. fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: RCT

Source: Lancet Oncology,
Date published: 11/10/2011

Category:

8.1.3 Antimetabolites | 8.2.3 Anti-lymphocyte monoclonal antibodies | Leukaemia

NeLM Area:

News

Abstract

Comment- full text for subscribers only

Results 1 - 10 of 162

Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next